Zotarolimus: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
== Zotarolimus == | |||
[[File:Zotarolimus.svg|thumb|right|Chemical structure of Zotarolimus]] | |||
Zotarolimus | '''Zotarolimus''' is a [[macrolide]] [[immunosuppressant]] drug that is primarily used in [[drug-eluting stents]] to prevent [[coronary artery disease|coronary artery]] restenosis. It is a derivative of [[sirolimus]], also known as rapamycin, and functions by inhibiting the [[mammalian target of rapamycin]] (mTOR), a key regulatory kinase involved in cell proliferation. | ||
== | == Mechanism of Action == | ||
Zotarolimus | Zotarolimus works by binding to the intracellular protein [[FKBP12]] (FK506-binding protein 12). This complex then inhibits the mTOR pathway, which is crucial for cell cycle progression. By blocking mTOR, zotarolimus effectively reduces the proliferation of [[smooth muscle cells]] in the arterial wall, thereby preventing restenosis. | ||
== Clinical | == Clinical Use == | ||
Zotarolimus is used | Zotarolimus is primarily used in [[drug-eluting stents]] (DES), which are implanted in patients with [[coronary artery disease]] to keep the arteries open. The drug is released slowly from the stent to prevent the growth of scar tissue and restenosis, which is the re-narrowing of the artery. | ||
== | == Pharmacokinetics == | ||
Zotarolimus is designed to be released locally from the stent over a period of time, allowing for targeted action at the site of the stent placement. This local delivery minimizes systemic exposure and reduces the risk of systemic side effects. | |||
== | == Side Effects == | ||
* [[ | As with other mTOR inhibitors, potential side effects of zotarolimus include [[immunosuppression]], which can increase the risk of infections. Other side effects may include delayed wound healing and [[thrombocytopenia]]. | ||
== Related Pages == | |||
* [[Sirolimus]] | |||
* [[Drug-eluting stent]] | * [[Drug-eluting stent]] | ||
* [[ | * [[Coronary artery disease]] | ||
* [[ | * [[Mammalian target of rapamycin]] | ||
[[Category: | [[Category:Immunosuppressants]] | ||
[[Category:Macrolides]] | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Latest revision as of 04:00, 13 February 2025
Zotarolimus[edit]
Zotarolimus is a macrolide immunosuppressant drug that is primarily used in drug-eluting stents to prevent coronary artery restenosis. It is a derivative of sirolimus, also known as rapamycin, and functions by inhibiting the mammalian target of rapamycin (mTOR), a key regulatory kinase involved in cell proliferation.
Mechanism of Action[edit]
Zotarolimus works by binding to the intracellular protein FKBP12 (FK506-binding protein 12). This complex then inhibits the mTOR pathway, which is crucial for cell cycle progression. By blocking mTOR, zotarolimus effectively reduces the proliferation of smooth muscle cells in the arterial wall, thereby preventing restenosis.
Clinical Use[edit]
Zotarolimus is primarily used in drug-eluting stents (DES), which are implanted in patients with coronary artery disease to keep the arteries open. The drug is released slowly from the stent to prevent the growth of scar tissue and restenosis, which is the re-narrowing of the artery.
Pharmacokinetics[edit]
Zotarolimus is designed to be released locally from the stent over a period of time, allowing for targeted action at the site of the stent placement. This local delivery minimizes systemic exposure and reduces the risk of systemic side effects.
Side Effects[edit]
As with other mTOR inhibitors, potential side effects of zotarolimus include immunosuppression, which can increase the risk of infections. Other side effects may include delayed wound healing and thrombocytopenia.
